Zhuoxin Liang1, Jinjian Fu1, Ling Li2, Rongsong Yi1, Shaolin Xu1, Jichang Chen1, Xiaohua Ye3, Eric McGrath4,5. 1. Department of Pediatric Intensive Care Unit, Department of Prevention and Health Care, Department of Pediatric, Department of Laboratory, Department of Neonatology, Liuzhou Maternity and Child Health Care Hospital, Liuzhou, China. 2. Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha, China. 3. Laboratory of Molecular Epidemiology, School of Public Health, Guangdong Pharmaceutical University, 283# Jianghai Dadao, Haizhu District, 510310, Guangzhou, China. smalltomato@163.com. 4. Children's Hospital of Michigan, Detroit, MI, USA. 5. Wayne State University School of Medicine, Detroit, MI, USA.
Abstract
BACKGROUND: Streptococcus pneumoniae (S. pneumoniae) is one of the most common pathogens which can cause morbidity and mortality in pediatric infections worldwide. This study aimed to describe the phenotypic and molecular characteristics of community-acquired pneumonia (CAP)-causing S. pneumoniae recovered from children in Western China. METHODS: We retrospectively enrolled pediatric patients younger than 5 years diagnosed with CAP. All 419 S. pneumoniae isolates were tested for antibiotic susceptibility, serotypes, virulence genes, resistance genes, and sequence types. The potential relationships between molecular characteristics were tested by correspondence analysis. RESULTS: Most of S. pneumoniae isolates were resistant to erythromycin, tetracycline, clindamycin and trimethoprim-sulfamethoxazole, with 93.8% isolates classified as multidrug resistant. The dominant STs were ST271 (30.8%) and ST320 (12.2%), while the prevailing serotypes were 19F (46.8%), 6B (11.5%), 23F (9.5%) and 19A (9.3%). The coverage rates of PCV-7 and PCV-13 were 73.03% and 86.16%, while the coverage rates of PCV13 among children aged < 1 year and 1-2 years were high in 93.18% and 93.62%. We also observed that CC271 expressed more of mef (A/E), lytA, rlrA and sipA than non-CC271 isolates. Moreover, there were strong corresponding relationships between molecular characteristics. CONCLUSIONS: The high coverage rate of PCV13 suggests the necessity of introducing the PCV13 vaccine in Western China. Our findings underscore the value of monitoring multiple molecular characteristics to provide new guidance for developing future pneumococcal vaccines.
BACKGROUND:Streptococcus pneumoniae (S. pneumoniae) is one of the most common pathogens which can cause morbidity and mortality in pediatric infections worldwide. This study aimed to describe the phenotypic and molecular characteristics of community-acquired pneumonia (CAP)-causing S. pneumoniae recovered from children in Western China. METHODS: We retrospectively enrolled pediatric patients younger than 5 years diagnosed with CAP. All 419 S. pneumoniae isolates were tested for antibiotic susceptibility, serotypes, virulence genes, resistance genes, and sequence types. The potential relationships between molecular characteristics were tested by correspondence analysis. RESULTS: Most of S. pneumoniae isolates were resistant to erythromycin, tetracycline, clindamycin and trimethoprim-sulfamethoxazole, with 93.8% isolates classified as multidrug resistant. The dominant STs were ST271 (30.8%) and ST320 (12.2%), while the prevailing serotypes were 19F (46.8%), 6B (11.5%), 23F (9.5%) and 19A (9.3%). The coverage rates of PCV-7 and PCV-13 were 73.03% and 86.16%, while the coverage rates of PCV13 among children aged < 1 year and 1-2 years were high in 93.18% and 93.62%. We also observed that CC271 expressed more of mef (A/E), lytA, rlrA and sipA than non-CC271 isolates. Moreover, there were strong corresponding relationships between molecular characteristics. CONCLUSIONS: The high coverage rate of PCV13 suggests the necessity of introducing the PCV13 vaccine in Western China. Our findings underscore the value of monitoring multiple molecular characteristics to provide new guidance for developing future pneumococcal vaccines.
Authors: Lone Simonsen; Robert J Taylor; Cynthia Schuck-Paim; Roger Lustig; Michael Haber; Keith P Klugman Journal: Lancet Respir Med Date: 2014-03-10 Impact factor: 30.700
Authors: Igor Rudan; Katherine L O'Brien; Harish Nair; Li Liu; Evropi Theodoratou; Shamim Qazi; Ivana Lukšić; Christa L Fischer Walker; Robert E Black; Harry Campbell Journal: J Glob Health Date: 2013-06 Impact factor: 4.413
Authors: M A Elemraid; S P Rushton; M D F Shirley; M F Thomas; D A Spencer; K M Eastham; F Hampton; R Gorton; K Pollard; A R Gennery; J E Clark Journal: Epidemiol Infect Date: 2012-10-19 Impact factor: 2.451
Authors: Rodrigo DeAntonio; Juan-Pablo Yarzabal; James Philip Cruz; Johannes E Schmidt; Jos Kleijnen Journal: Hum Vaccin Immunother Date: 2016-06-07 Impact factor: 3.452
Authors: Pedro H Silva; Yaneisi Vázquez; Camilo Campusano; Angello Retamal-Díaz; Margarita K Lay; Christian A Muñoz; Pablo A González; Alexis M Kalergis; Susan M Bueno Journal: Front Cell Infect Microbiol Date: 2022-09-26 Impact factor: 6.073